Nelarabine CAS NO.121032-29-9
- FOB Price: USD: 240.00-240.00 /Gram Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: L/C,D/A,D/P,T/T,
- Available Specifications:
99%(1-5)Gram99%(5-10)Gram
- Product Details
Keywords
- 121032-29-9
- Heterocycles
- Intermediates & Fine Chemicals
Quick Details
- ProName: Nelarabine
- CasNo: 121032-29-9
- Molecular Formula: C11H15N5O5
- Appearance: White crystalline
- Application: antineoplastic
- DeliveryTime: Shipped in 15 days after payment
- PackAge: according to customers' requirements
- Port: China main port
- ProductionCapacity: 100 Metric Ton/Week
- Purity: 99%
- Storage: Cool Dry Place
- Transportation: International express delivery
- LimitNum: 1 Gram
Superiority
Our company has been in existence for 10 years since its establishment. We have our own unique team. The company integrates independent research and development, production and sales. We have established famous brands at home and abroad. At present, our customers have spread all over the world, we have rich Transportation experience, we aim to serve customers, to help customers, solve problems for customers. Look forward to working with you!
Details
Application:
Nelarabine is mainly used for patients who have received at least two chemotherapy regimens but still have no response, or have occurred recurrent acute T-cell lymphoblastic leukemia and T-cell lymphoblastic lymphoma.Adult patients received nelarabine i.v. over 2 hours on days 1, 3 and 5 in every 21 days with the recommendation dose of 1500mg/m2 in every 21 days and without dilution; pediatric patients received this regimen over 1 hour for 5 consecutive days with the recommendation dose of 650mg/m2 in every 21 days, without dilution. The recommended treatment period for adults and children is unspecified. In clinical trials, unless the patient get worse and cannot tolerate toxicity. They should treated with bone marrow transplant immediately or no longer be treated.
Nelarabine is mainly used for patients who have received at least two chemotherapy regimens but still have no response, or have occurred recurrent acute T-cell lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Adult patients received nelarabine i.v. over 2 hours on days 1, 3 and 5 in every 21 days with the recommendation dose of 1500mg/m2 in every 21 days and without dilution; pediatric patients received this regimen over 1 hour for 5 consecutive days with the recommendation dose of 650mg/m2 in every 21 days, without dilution. The recommended treatment period for adults and children is unspecified. In clinical trials, unless the patient get worse and cannot tolerate toxicity. They should treated with bone marrow transplant immediately or no longer be treated. |